INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Instituto
Universidad Austral de Chile
Valdivia, ChilePublicaciones en colaboración con investigadores/as de Universidad Austral de Chile (27)
2019
-
Tanycytes: A rich morphological history to underpin future molecular and physiological investigations
Journal of Neuroendocrinology, Vol. 31, Núm. 3
2017
-
Blood-brain barrier and foetal-onset hydrocephalus, with a view on potential novel treatments beyond managing CSF flow
Fluids and Barriers of the CNS, Vol. 14, Núm. 1
-
Regulation of membrane ruffling by polarized STIM1 and ORAI1 in cortactin-rich domains
Scientific Reports, Vol. 7, Núm. 1
2016
-
A pharmacist's role in the individualization of treatment of HIV patients
Personalized Medicine, Vol. 13, Núm. 2, pp. 169-188
-
Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356
Autophagy
-
Gene–gene interactions between DRD3, MRP4 and CYP2B6 polymorphisms and its influence on the pharmacokinetic parameters of efavirenz in HIV infected patients
Drug Metabolism and Pharmacokinetics, Vol. 31, Núm. 5, pp. 349-355
-
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
Autophagy, Vol. 12, Núm. 1, pp. 1-222
-
Influence of the number of daily pills and doses on adherence to antiretroviral treatment: A 7-year study
Journal of Clinical Pharmacy and Therapeutics, Vol. 41, Núm. 1, pp. 34-39
2014
-
Dose reduction of efavirenz: An observational study describing cost-effectiveness, pharmacokinetics and pharmacogenetics
Pharmacogenomics, Vol. 15, Núm. 7, pp. 997-1006
-
Population pharmacokinetic/pharmacogenetic model of lopinavir/ritonavir in HIV-infected patients
Personalized Medicine, Vol. 11, Núm. 7, pp. 693-704
2013
-
Impact of a pharmaceutical care program on clinical evolution and antiretroviral treatment adherence: A 5-year study
Patient Preference and Adherence, Vol. 7, pp. 729-739
-
Nuevas estrategias en la optimización posológica de lopinavir/ritonavir en pacientes infectados por el virus de la inmunodeficiencia humana
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 31, Núm. 1, pp. 36-43
2011
-
Population Pharmacokinetic/Pharmacogenetic Model for Optimization of Efavirenz Therapy in Caucasian HIV-Infected Patients
Antimicrobial Agents and Chemotherapy, Vol. 55, Núm. 11, pp. 5314-5324
-
Population pharmacokinetic/pharmacogenetic model for optimization of Efavirenz therapy in caucasian HIV-infected patients
Antimicrobial Agents and Chemotherapy, Vol. 55, Núm. 11, pp. 5314-5324
-
Population pharmacokinetics of lopinavir/ritonavir (kaletra) in HIV-infected patients
Therapeutic Drug Monitoring, Vol. 33, Núm. 5, pp. 573-582
2010
-
Cell organization of the rat pars tuberalis. Evidence for open communication between pars tuberalis cells, cerebrospinal fluid and tanycytes
Cell and Tissue Research, Vol. 339, Núm. 2, pp. 359-381
-
The convergence of therapeutic drug monitoring and pharmacogenetic testing to optimize efavirenz therapy
Therapeutic Drug Monitoring, Vol. 32, Núm. 5, pp. 579-585
-
The design of barriers in the hypothalamus allows the median eminence and the arcuate nucleus to enjoy private milieus: The former opens to the portal blood and the latter to the cerebrospinal fluid
Peptides, Vol. 31, Núm. 4, pp. 757-776
2009
-
Hyperhidrosis in association with efavirenz
AIDS Patient Care and STDs, Vol. 23, Núm. 3, pp. 143-145